CN1864717A - Method for extracting Chinese lantern plant steride and pharmaceutical composition thereof - Google Patents
Method for extracting Chinese lantern plant steride and pharmaceutical composition thereof Download PDFInfo
- Publication number
- CN1864717A CN1864717A CN 200610010153 CN200610010153A CN1864717A CN 1864717 A CN1864717 A CN 1864717A CN 200610010153 CN200610010153 CN 200610010153 CN 200610010153 A CN200610010153 A CN 200610010153A CN 1864717 A CN1864717 A CN 1864717A
- Authority
- CN
- China
- Prior art keywords
- steride
- chemical compound
- chinese lantern
- lantern plant
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001465382 Physalis alkekengi Species 0.000 title claims abstract description 85
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 36
- 238000000034 method Methods 0.000 title claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000000843 powder Substances 0.000 claims abstract description 10
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 9
- 239000000284 extract Substances 0.000 claims abstract description 8
- 238000001035 drying Methods 0.000 claims abstract description 6
- 239000000706 filtrate Substances 0.000 claims abstract description 5
- 238000003809 water extraction Methods 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 83
- 241001164374 Calyx Species 0.000 claims description 19
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 claims description 18
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 claims description 18
- 229930014456 matrine Natural products 0.000 claims description 18
- 241001106044 Physalis Species 0.000 claims description 11
- 230000000274 adsorptive effect Effects 0.000 claims description 10
- 229920005989 resin Polymers 0.000 claims description 10
- 239000011347 resin Substances 0.000 claims description 10
- 244000153234 Hibiscus abelmoschus Species 0.000 claims description 6
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims description 6
- 229940093265 berberine Drugs 0.000 claims description 6
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims description 6
- 230000006837 decompression Effects 0.000 claims description 5
- 229920002101 Chitin Polymers 0.000 claims description 4
- 238000001179 sorption measurement Methods 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 6
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 5
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 5
- 150000001298 alcohols Chemical class 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 description 68
- 230000006793 arrhythmia Effects 0.000 description 68
- 208000031225 myocardial ischemia Diseases 0.000 description 38
- 230000037396 body weight Effects 0.000 description 29
- 230000006872 improvement Effects 0.000 description 21
- 238000010253 intravenous injection Methods 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 15
- 241000700157 Rattus norvegicus Species 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 8
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 8
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 8
- 206010047302 ventricular tachycardia Diseases 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 5
- 230000033764 rhythmic process Effects 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000002028 premature Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229940039750 aconitine Drugs 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 2
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- 240000001624 Espostoa lanata Species 0.000 description 2
- 235000009161 Espostoa lanata Nutrition 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Disclosed is a method for extracting Chinese lantern plant steride and pharmaceutical composition wherein the extracting process comprises: (1) alcohol or water extraction of fruit, rhizome and/or sepal, (2) purifying the extract, (3) eluting and concentrating the extract into concrete or dried powder, (4) dissolving the concrete or dried powder with alcohols, filtering, and drying the filtrate. The obtained pharmaceutical composition can be used for treating cardiovascular and cerebrovascular diseases.
Description
Technical field
The present invention relates to a kind of extracting method and pharmaceutical composition thereof of ingredient.
Background technology
The medicine for the treatment of cardiovascular and cerebrovascular disease in the market mostly is Western medicine, is easy to generate drug resistance and stronger toxic and side effects, and itself causes ARR generation again at the ARR while Western medicine of treatment.Chinese medicine was making encouraging progress aspect the treatment cardiovascular and cerebrovascular disease in recent years, but how with traditional Chinese medical science Cheng Fangwei object of study, the research of new Chinese medicinal formulae seldom.The Chinese lantern plant steride chemical compound derives from Calyx Seu Fructus Physalis, and the traditional Chinese medical science is thought the Calyx seu Fructus physalis mildly bitter flavor, returns lung meridian, has heat-clearing and toxic substances removing, and sore-throat relieving reduces phlegm, the diuretic effect; Be used to control the hectic fever due to YIN-deficiency consumptive fever, phlegm-heat cough, laryngopharynx swelling and pain, silent, jaundice, edema, dysuria, day bubble eczema.So, the report of present Chinese lantern plant steride compounds for treating cardiovascular and cerebrovascular diseases still of no use.
Summary of the invention
The present inventor finds that in the research of Calyx seu Fructus physalis the Chinese lantern plant steride chemical compound has the effect of prevention and treatment to cardiovascular and cerebrovascular diseases such as arrhythmia, myocardial ischemia, cerebrovascular sclerosis, cardiovascular and cerebrovascular vessel thromboembolism and hypertension.The Chinese lantern plant steride chemical compound extracts by the following method: (one) cleans, pulverizes back alcohol or water extraction with Calyx seu Fructus physalis fruit, rhizome and/or Constellation calyx; (2) filter the extracting solution of collecting, carry out adsorption and purification by chitin and macroporous adsorptive resins successively again; (3) be that 50%~90% alcohol carries out eluting to macroporous adsorptive resins with concentration, collect eluent, under decompression or condition of normal pressure, be condensed into extractum or dry powder; (4) extractum or dry powder reuse concentration are 60%~90% alcohol dissolving, filter, and filtrate promptly obtains the Chinese lantern plant steride chemical compound through drying under reduced pressure.The pharmaceutical composition that contains the Chinese lantern plant steride chemical compound is made by 65~75% Chinese lantern plant steride chemical compound, 15~25% matrine and 5~15% Radix Et Rhizoma Rhei by weight percentage.The pharmaceutical composition that contains the Chinese lantern plant steride chemical compound is made by 45~55% Chinese lantern plant steride chemical compound, 25~35% matrine and 15~25% berberine by weight percentage.The pharmaceutical composition that contains the Chinese lantern plant steride chemical compound is made by 55~65% Chinese lantern plant steride chemical compound, 30~40% matrine and 1~10% Moschus by weight percentage.The method that the present invention extracts the Chinese lantern plant steride chemical compound is simple, and the Chinese lantern plant steride compound purity is up to more than 50%.The pharmaceutical composition that contains the Chinese lantern plant steride chemical compound among the present invention can be used for treating arrhythmia or myocardial ischemia, and effective percentage is respectively 85%, 90% and 85%.
The specific embodiment
The specific embodiment one: present embodiment Chinese lantern plant steride chemical compound extracts by the following method: (one) cleans, pulverizes back alcohol or water extraction with Calyx seu Fructus physalis fruit, rhizome and/or Constellation calyx; (2) filter the extracting solution of collecting, carry out adsorption and purification by chitin and macroporous adsorptive resins successively again; (3) be that 50%~90% alcohol carries out eluting to macroporous adsorptive resins with concentration, collect eluent, under decompression or condition of normal pressure, be condensed into extractum or dry powder; (4) extractum or dry powder reuse concentration are 60%~90% alcohol dissolving, filter, and filtrate promptly obtains the Chinese lantern plant steride chemical compound through drying under reduced pressure.
The Chinese lantern plant steride chemical compound that extracts with present embodiment carries out animal experiment, and (the purity same purity of the Chinese lantern plant steride chemical compound of this test use is 70%; All to be dissolved in concentration be injection again behind 5% the glucose to the Chinese lantern plant steride chemical compound in the test, and injected dose is 10mL):
(1) anoxia survival test: this experiment divides 4 groups to carry out, and 10 every group, body weight are the Kunming mouse of 18~22g, and the 1st group of mice is by every kilogram of intravenous injection 10mL of body weight normal saline; The 2nd group of mice is by every kilogram of intravenous injection 5mg of body weight Chinese lantern plant steride chemical compound; The 3rd group of mice is by every kilogram of intravenous injection 15mg of body weight Chinese lantern plant steride chemical compound; The 4th group of mice is by every kilogram of intravenous injection 75mg of body weight Chinese lantern plant steride chemical compound; Behind the injection 30min mice is put in the 500mL port grinding bottle that contains the 3g sodica calx, change bottle cap behind the vaseline of bottleneck way, the record mouse diing time.It is as shown in table 1 that each organizes mouse diing time.
Table 1
Group | Time-to-live (min) |
1 | 47.44±11.69 |
2 | 57.88±13.21 |
3 | 64.97±15.06 |
4 | 73.99±15.21 |
2nd, 3 compare with the 1st group and to have significant difference P<0.05 with 4 groups.Result of the test explanation Chinese lantern plant steride chemical compound can prolong the complete airtight mice time-to-live, and increases anti-anoxia ability.
(2) Chinese lantern plant steride chemical compound ARR influence that aconitine is brought out: this experiment divides 4 groups and carries out, every group 10, body weight are the Healthy female Wistar rats of 200~230g, and the 1st group of female Wistar rats is by every kilogram of intravenous injection 10mL of body weight normal saline; The 2nd group of female Wistar rats is by every kilogram of intravenous injection 5mg of body weight Chinese lantern plant steride chemical compound; The 3rd group of female Wistar rats is by every kilogram of intravenous injection 15mg of body weight Chinese lantern plant steride chemical compound; The 4th group of female Wistar rats is by every kilogram of intravenous injection 75mg of body weight Chinese lantern plant steride chemical compound; Anaesthetize by every kilogram of lumbar injection 5mg of body weight, 20% urethane behind the 30min; It is fixing and link to each other with BL-420 biological function experimental system and to scan electrocardio then rat to be faced upward the position, treat that the rat electrocardio shows that stable back is at the 1st group of rat sublingual vein injecting normal saline,, finish in the injection 5s by every kilogram of sublingual vein of body weight injection 1mL, 0.04% aconitine the 2nd, 3 and 4 group of rat; The time of origin of recording room premature beat (VP), and statistics ventricular tachycardia (VT), chamber the quiver incidence rate and the sinus rhythm recovery rate of (VF).It is as shown in table 2 that each organizes rat VP time of origin, VT incidence rate, VF incidence rate and sinus rhythm recovery rate.
Table 2
Group | The VT incidence rate | The VF incidence rate | The sinus rhythm recovery rate | VP time of origin (min) |
1 | 8/10 | 2/10 | 6/10 | 1.43±0.52 |
2 | 4/10 | 1/10 | 8/10 | 2.03±0.87 |
3 | 2/10 | 1/10 | 9/10 | 3.23±0.97 |
4 | 1/10 | 0 | 10/10 | 4.26±1.19 |
The 3rd compares with the 1st group and to have significant difference P<0.05 with 4 groups.Result of the test explanation Chinese lantern plant steride chemical compound has the arrhythmia effect that anti-aconitine brings out.
(3) Chinese lantern plant steride chemical compound chamber that chloroform the is brought out influence of quivering: this experiment divides 4 groups to be carried out, and 10 every group, body weight are the Kunming mouse of 18~22g, and the 1st group of mice is by every kilogram of intravenous injection 10mL of body weight normal saline; The 2nd group of mice is by every kilogram of intravenous injection 5mg of body weight Chinese lantern plant steride chemical compound; The 3rd group of mice is by every kilogram of intravenous injection 15mg of body weight Chinese lantern plant steride chemical compound; The 4th group of mice is by every kilogram of intravenous injection 75mg of body weight Chinese lantern plant steride chemical compound; In injection 2~3min mice put into one by one and contain chloroform, inverted beaker and (soak the beaker of putting into 500mL behind the cotton balls with the 5mL chloroform, change Mus at every turn and add the 0.5mL chloroform) to cotton balls, after ceasing breathing, mice takes out immediately, the scanning electrocardio that links to each other with BL-420 biological function experimental system, the recording room incidence rate of quivering.It is as shown in table 3 that each organizes the mice chamber incidence rate of quivering.
Table 3
Group | Test mice (only) | The generation chamber mice (only) that quivers | The chamber incidence rate (%) of quivering |
1 | 10 | 9 | 90 |
2 | 10 | 3 | 30 |
3 | 10 | 3 | 30 |
4 | 10 | 1 | 10 |
2nd, 3 compare with the 1st group and to have significant difference P<0.05 with 4 groups.Result of the test explanation Chinese lantern plant steride chemical compound has the arrhythmia effect that anti-chloroform brings out.
(4) protective effect of Chinese lantern plant steride chemical compound myocardial ischemia that pituitrin is brought out: this experiment divides 4 groups and carries out, every group 14, body weight are the healthy Wistar rat of 200~230g, and the 1st group of healthy Wistar rat is by every kilogram of intravenous injection 10mL of body weight normal saline; The 2nd group of health, to the Wistar rat of pituitrin sensitivity (obviously raise by ECG T wave behind every kilogram of sublingual vein injection of pituitrin of body weight 1U, the ST section is raised above 0.1mV) by every kilogram of intravenous injection 10mL of body weight normal saline; The 3rd group of health, to the Wistar rat of pituitrin sensitivity by every kilogram of intravenous injection 5mg of body weight Chinese lantern plant steride chemical compound; The 4th group of health, to the Wistar rat of pituitrin sensitivity by every kilogram of intravenous injection 15mg of body weight Chinese lantern plant steride chemical compound; The 5th group of health, to the Wistar rat of pituitrin sensitivity by every kilogram of intravenous injection 75mg of body weight Chinese lantern plant steride chemical compound; Anaesthetize by every kilogram of lumbar injection 5mg of body weight, 20% urethane after the 1h; Then rat is faced upward the fixing and scanning electrocardio that links to each other with BL-420 biological function experimental system in position,, inject the 1U pituitrin by every kilogram of sublingual vein of body weight the 2nd, 3,4 and 5 group of rat at the 1st group of rat sublingual vein injecting normal saline.Abdominal aortic blood behind the pituitrin injection 60min, centrifugalize serum is measured the content of lactic acid dehydrogenase in the serum (LDH), superoxide dismutase (SOD), malonaldehyde (MDA) again.It is as shown in table 4 that each organizes the content of rat LDH, SOD and MDA.
Table 4
Group | LDH(U/L) | SOD(nmol/mL) | MDA(U/mL) |
1 | 8803.33±1494.82 bcde | 2.80±0.79 b | 95.81±9.85 bc |
2 | 10923.42±1258.82 acde | 4.91±1.66 acde | 76.41±8.30 ade |
3 | 9203.33±1694.52 abe | 3.25±0.84 b | 80.93±8.65 abe |
4 | 9434.36±2111.03 abe | 3.12±1.46 b | 88.37±10.63 ab |
5 | 9003.52±1584.37 bcd | 2.92±0.80 b | 91.81±9.85 bc |
A represents to compare with the 1st group and has significant difference P<0.05; B represents to have significant difference P<0.05 with the 2nd group of ratio; C represents to compare with the 3rd group and has significant difference P<0.05; D represents to compare with the 4th group and has significant difference P<0.05; E represents to compare with the 5th group and has significant difference P<0.05.Result of the test explanation Chinese lantern plant steride chemical compound has function of resisting myocardial ischemia.
The specific embodiment two: the difference of the present embodiment and the specific embodiment one is: alcohol is ethanol, propanol or butanols.Other is identical with embodiment one.
The specific embodiment three: the difference of the present embodiment and the specific embodiment one is: the weight of middle alcohol of step () or water is Calyx seu Fructus physalis fruit, rhizome and/or Constellation calyx gross weight 4~10 times.Other step with
Embodiment one is identical.
The specific embodiment four: the difference of the present embodiment and the specific embodiment one is: the alcohol reflux eluting 1.8~2.2h that in the step (three) with 4~5 times of macroporous adsorptive resins volumes, temperature is 50~70 ℃.Other step is identical with embodiment one.
The specific embodiment five: the difference of the present embodiment and the specific embodiment one is: decompression or normal pressure thickening temperature are lower than 70 ℃ all the time in the step (three); Concentrating under reduced pressure pressure is less than 10
-3Pa.Other step with
Embodiment one is identical.
The specific embodiment six: the difference of the present embodiment and the specific embodiment one is: drying under reduced pressure pressure is less than 10 in the step (four)
-3Pa, temperature is lower than 70 ℃.Other step is identical with embodiment one.
The specific embodiment seven: present embodiment and the specific embodiment one, three or fours' difference is: alcohol is that volumetric concentration is 70% ethanol.Other is identical with embodiment one, three or four.
The specific embodiment eight: the difference of the present embodiment and the specific embodiment one is: be 5~9 times the water heated and boiled Calyx seu Fructus physalis fruit, rhizome of Calyx seu Fructus physalis fruit, rhizome and/or Constellation calyx gross weight and/or Constellation calyx 3 times in the step () with weight, and each 35~45min.Other step is identical with embodiment one.
The specific embodiment nine: the difference of the present embodiment and the specific embodiment one is: macroporous adsorptive resins is the DM130 macroporous adsorptive resins in the step (two).Other step is identical with embodiment one.
The specific embodiment ten: present embodiment Chinese lantern plant steride chemical compound extracts by the following method: (one) cleans, pulverizes back alcohol or water extraction with Calyx seu Fructus physalis fruit, rhizome and/or Constellation calyx; (2) filter the extracting solution of collecting, carry out chitin absorption again; (3) collect adsorption liquid, under decompression or condition of normal pressure, be condensed into extractum or dry powder; (4) extractum or dry powder reuse concentration are 60%~90% alcohol dissolving, filter, and filtrate promptly obtains the Chinese lantern plant steride chemical compound through drying under reduced pressure.
The specific embodiment 11: the pharmaceutical composition that present embodiment contains the Chinese lantern plant steride chemical compound is made by 65~75% Chinese lantern plant steride chemical compound, 15~25% matrine and 5~15% Radix Et Rhizoma Rhei by weight percentage.
The pharmaceutical composition that present embodiment is made is used for the treatment of arrhythmia.Table 5 is the ARR clinical pharmacodynamics reports of present embodiment medicine composite for curing.
Usage and dosage: obey every day three times, take present embodiment pharmaceutical composition 45mg by every kilogram of patient body weight at every turn.
Male's patients with arrhythmia at 30 55~60 years old age of example is carried out treatment in 10~20 days; conditions of patients is clearly better accounts for 55% (ventricular premature contraction disappears, ventricular tachycardia disappears, sinus rhythm recover); conditions of patients is slight improve account for 30% (the ventricular premature contraction number of times reduces, ventricular tachycardia number of times reduce), the patient that fails to respond to any medical treatment accounts for 15%.The ARR effect of present embodiment Drug therapy is as shown in table 5, and wherein state of an illness diagnosis is accepted and believed regular hospital and provided electrocardiogram.
Table 5
Sequence number | Age | Disease or symptom | Treatment time | Therapeutic effect |
1 | 56 | Arrhythmia | 12 | Be clearly better |
2 | 56 | Arrhythmia | 17 | Be clearly better |
3 | 60 | Arrhythmia | 12 | Be clearly better |
4 | 55 | Arrhythmia | 19 | Be clearly better |
5 | 58 | Arrhythmia | 12 | Be clearly better |
6 | 58 | Arrhythmia | 15 | Be clearly better |
7 | 57 | Arrhythmia | 18 | Be clearly better |
8 | 59 | Arrhythmia | 20 | Be clearly better |
9 | 60 | Arrhythmia | 16 | Be clearly better |
10 | 58 | Arrhythmia | 17 | Be clearly better |
11 | 56 | Arrhythmia | 17 | Be clearly better |
12 | 58 | Arrhythmia | 11 | Be clearly better |
13 | 57 | Arrhythmia | 13 | Be clearly better |
14 | 55 | Arrhythmia | 13 | Be clearly better |
15 | 60 | Arrhythmia | 10 | Be clearly better |
16 | 57 | Arrhythmia | 19 | Be clearly better |
17 | 56 | Arrhythmia | 20 | Be clearly better |
18 | 57 | Arrhythmia | 14 | The slight improvement |
19 | 58 | Arrhythmia | 14 | The slight improvement |
20 | 58 | Arrhythmia | 13 | The slight improvement |
21 | 57 | Arrhythmia | 15 | The slight improvement |
22 | 56 | Arrhythmia | 14 | The slight improvement |
23 | 60 | Arrhythmia | 17 | The slight improvement |
24 | 57 | Arrhythmia | 18 | The slight improvement |
25 | 57 | Arrhythmia | 17 | The slight improvement |
26 | 59 | Arrhythmia | 15 | The slight improvement |
27 | 57 | Arrhythmia | 15 | Invalid |
28 | 55 | Arrhythmia | 14 | Invalid |
29 | 59 | Arrhythmia | 14 | Invalid |
30 | 57 | Arrhythmia | 13 | Invalid |
The specific embodiment 12: the difference of the present embodiment and the specific embodiment 11 is: the pharmaceutical composition that contains the Chinese lantern plant steride chemical compound is made by 66~74% Chinese lantern plant steride chemical compound, 16~24% matrine and 6~14% Radix Et Rhizoma Rhei by weight percentage.
The specific embodiment 13: the difference of the present embodiment and the specific embodiment 11 is: the pharmaceutical composition that contains the Chinese lantern plant steride chemical compound is made by 70% Chinese lantern plant steride chemical compound, 20% matrine and 10% Radix Et Rhizoma Rhei by weight percentage.
The specific embodiment 14: the pharmaceutical composition that present embodiment contains the Chinese lantern plant steride chemical compound is made by 45~55% Chinese lantern plant steride chemical compound, 25~35% matrine and 15~25% berberine by weight percentage.
The pharmaceutical composition that present embodiment is made is used for the treatment of arrhythmia.Table 6 is the ARR clinical pharmacodynamics reports of present embodiment medicine composite for curing.
Usage and dosage: obey every day three times, take present embodiment pharmaceutical composition 45mg by every kilogram of patient body weight at every turn.
Male's patients with arrhythmia at 30 55~60 years old age of example is carried out treatment in 10~20 days; conditions of patients is clearly better accounts for 60% (ventricular premature contraction disappears, ventricular tachycardia disappears, sinus rhythm recover); conditions of patients is slight improve account for 30% (the ventricular premature contraction number of times reduces, ventricular tachycardia number of times reduce), the patient that fails to respond to any medical treatment accounts for 10%.The ARR effect of present embodiment Drug therapy is as shown in table 6, and wherein state of an illness diagnosis is accepted and believed regular hospital and provided electrocardiogram.
Table 6
Sequence number | Age | Disease or symptom | Treatment time | Therapeutic effect |
1 | 57 | Arrhythmia | 15 | Be clearly better |
2 | 59 | Arrhythmia | 14 | Be clearly better |
3 | 57 | Arrhythmia | 17 | Be clearly better |
4 | 55 | Arrhythmia | 18 | Be clearly better |
5 | 59 | Arrhythmia | 17 | Be clearly better |
6 | 57 | Arrhythmia | 15 | Be clearly better |
7 | 57 | Arrhythmia | 15 | Be clearly better |
8 | 59 | Arrhythmia | 14 | Be clearly better |
9 | 60 | Arrhythmia | 14 | Be clearly better |
10 | 58 | Arrhythmia | 13 | Be clearly better |
11 | 56 | Arrhythmia | 17 | Be clearly better |
12 | 58 | Arrhythmia | 11 | Be clearly better |
13 | 57 | Arrhythmia | 13 | Be clearly better |
14 | 55 | Arrhythmia | 13 | Be clearly better |
15 | 58 | Arrhythmia | 10 | Be clearly better |
16 | 58 | Arrhythmia | 19 | Be clearly better |
17 | 57 | Arrhythmia | 20 | Be clearly better |
18 | 59 | Arrhythmia | 14 | Be clearly better |
19 | 60 | Arrhythmia | 13 | The slight improvement |
20 | 58 | Arrhythmia | 13 | The slight improvement |
21 | 60 | Arrhythmia | 15 | The slight improvement |
22 | 58 | Arrhythmia | 14 | The slight improvement |
23 | 56 | Arrhythmia | 11 | The slight improvement |
24 | 58 | Arrhythmia | 13 | The slight improvement |
25 | 57 | Arrhythmia | 13 | The slight improvement |
26 | 55 | Arrhythmia | 10 | The slight improvement |
27 | 60 | Arrhythmia | 19 | The slight improvement |
28 | 57 | Arrhythmia | 20 | Invalid |
29 | 56 | Arrhythmia | 14 | Invalid |
30 | 60 | Arrhythmia | 11 | Invalid |
The specific embodiment 15: the difference of the present embodiment and the specific embodiment 14 is: the pharmaceutical composition that contains the Chinese lantern plant steride chemical compound is made by 46~54% Chinese lantern plant steride chemical compound, 26~34% matrine and 16~24% berberine by weight percentage.
The specific embodiment 16: the difference of the present embodiment and the specific embodiment 14 is: the pharmaceutical composition that contains the Chinese lantern plant steride chemical compound is made by 50% Chinese lantern plant steride chemical compound, 30% matrine and 20% berberine by weight percentage.
The specific embodiment 17: the pharmaceutical composition that present embodiment contains the Chinese lantern plant steride chemical compound is made by 55~65% Chinese lantern plant steride chemical compound, 30~40% matrine and 1~10% Moschus by weight percentage.
The pharmaceutical composition that present embodiment is made is used for the treatment of myocardial ischemia.Table 7 is clinical pharmacodynamics reports of present embodiment medicine composite for curing myocardial ischemia.
Usage and dosage: obey every day three times, take present embodiment pharmaceutical composition 45mg by every kilogram of patient body weight at every turn.
Male's myocardial ischemia patient to 30 55~60 years old age of example carries out treatment in 10~20 days, conditions of patients is clearly better accounts for 75% (electrocardio T ripple recovers, ST section recover), conditions of patients is slight improve account for 10% (electrocardio T wave height reduces, ST section reduce), the patient that fails to respond to any medical treatment accounts for 15%.The effect of present embodiment Drug therapy myocardial ischemia is as shown in table 7, and wherein state of an illness diagnosis is accepted and believed regular hospital and provided electrocardiogram.
Table 7
Sequence number | Age | Disease or symptom | Treatment time | Therapeutic effect |
1 | 59 | Myocardial ischemia | 17 | Be clearly better |
2 | 57 | Myocardial ischemia | 14 | Be clearly better |
3 | 57 | Myocardial ischemia | 17 | Be clearly better |
4 | 59 | Myocardial ischemia | 10 | Be clearly better |
5 | 60 | Myocardial ischemia | 19 | Be clearly better |
6 | 58 | Myocardial ischemia | 20 | Be clearly better |
7 | 56 | Myocardial ischemia | 14 | Be clearly better |
8 | 58 | Myocardial ischemia | 13 | Be clearly better |
9 | 57 | Myocardial ischemia | 13 | Be clearly better |
10 | 55 | Myocardial ischemia | 15 | Be clearly better |
11 | 58 | Myocardial ischemia | 14 | Be clearly better |
12 | 58 | Myocardial ischemia | 11 | Be clearly better |
13 | 57 | Myocardial ischemia | 13 | Be clearly better |
14 | 55 | Myocardial ischemia | 13 | Be clearly better |
15 | 58 | Myocardial ischemia | 10 | Be clearly better |
16 | 58 | Myocardial ischemia | 19 | Be clearly better |
17 | 57 | Myocardial ischemia | 20 | Be clearly better |
18 | 59 | Myocardial ischemia | 18 | Be clearly better |
19 | 60 | Myocardial ischemia | 13 | Be clearly better |
20 | 58 | Myocardial ischemia | 13 | Be clearly better |
21 | 60 | Myocardial ischemia | 15 | Be clearly better |
22 | 58 | Myocardial ischemia | 14 | Be clearly better |
23 | 56 | Myocardial ischemia | 11 | Be clearly better |
24 | 60 | Myocardial ischemia | 13 | The slight improvement |
25 | 58 | Myocardial ischemia | 13 | The slight improvement |
26 | 56 | Myocardial ischemia | 10 | The slight improvement |
27 | 58 | Myocardial ischemia | 19 | Invalid |
28 | 57 | Myocardial ischemia | 20 | Invalid |
29 | 55 | Myocardial ischemia | 15 | Invalid |
30 | 60 | Myocardial ischemia | 17 | Invalid |
The specific embodiment 18: the difference of the present embodiment and the specific embodiment 17 is: the pharmaceutical composition that contains the Chinese lantern plant steride chemical compound is made by 56~64% Chinese lantern plant steride chemical compound, 31~39% matrine and 2~9% Moschus by weight percentage.
The specific embodiment 19: the difference of the present embodiment and the specific embodiment 17 is: the pharmaceutical composition that contains the Chinese lantern plant steride chemical compound is made by 60% Chinese lantern plant steride chemical compound, 35% matrine and 5% Moschus by weight percentage.
Claims (10)
1, the extracting method of Chinese lantern plant steride chemical compound is characterized in that the Chinese lantern plant steride chemical compound extracts by the following method: (one) cleans, pulverizes back alcohol or water extraction with Calyx seu Fructus physalis fruit, rhizome and/or Constellation calyx; (2) filter the extracting solution of collecting, carry out adsorption and purification by chitin and macroporous adsorptive resins successively again; (3) be that 50%~90% alcohol carries out eluting to macroporous adsorptive resins with concentration, collect eluent, under decompression or condition of normal pressure, be condensed into extractum or dry powder; (4) extractum or dry powder reuse concentration are 60%~90% alcohol dissolving, filter, and filtrate promptly obtains the Chinese lantern plant steride chemical compound through drying under reduced pressure.
2, the extracting method of Chinese lantern plant steride chemical compound according to claim 1 is characterized in that alcohol is ethanol, propanol or butanols.
3, the extracting method of Chinese lantern plant steride chemical compound according to claim 1, the weight that it is characterized in that middle alcohol of step () or water are Calyx seu Fructus physalis fruit, rhizome and/or Constellation calyx gross weight 4~10 times.
4, the extracting method of Chinese lantern plant steride chemical compound according to claim 1 is characterized in that in the step (three) with 4~5 times of macroporous adsorptive resins volumes, temperature being alcohol reflux eluting 1.8~2.2h of 50~70 ℃.
5, the pharmaceutical composition that contains the Chinese lantern plant steride chemical compound, the pharmaceutical composition that it is characterized in that containing the Chinese lantern plant steride chemical compound are made by 65~75% Chinese lantern plant steride chemical compound, 15~25% matrine and 5~15% Radix Et Rhizoma Rhei by weight percentage.
6, the pharmaceutical composition that contains the Chinese lantern plant steride chemical compound according to claim 5, the pharmaceutical composition that it is characterized in that containing the Chinese lantern plant steride chemical compound are made by 66~74% Chinese lantern plant steride chemical compound, 16~24% matrine and 6~14% Radix Et Rhizoma Rhei by weight percentage.
7, the pharmaceutical composition that contains the Chinese lantern plant steride chemical compound, the pharmaceutical composition that it is characterized in that containing the Chinese lantern plant steride chemical compound are made by 45~55% Chinese lantern plant steride chemical compound, 25~35% matrine and 15~25% berberine by weight percentage.
8, the pharmaceutical composition that contains the Chinese lantern plant steride chemical compound according to claim 7, the pharmaceutical composition that it is characterized in that containing the Chinese lantern plant steride chemical compound are made by 46~54% Chinese lantern plant steride chemical compound, 26~34% matrine and 16~24% berberine by weight percentage.
9, the pharmaceutical composition that contains the Chinese lantern plant steride chemical compound, the pharmaceutical composition that it is characterized in that containing the Chinese lantern plant steride chemical compound are made by 55~65% Chinese lantern plant steride chemical compound, 30~40% matrine and 1~10% Moschus by weight percentage.
10, the pharmaceutical composition that contains the Chinese lantern plant steride chemical compound according to claim 9, the pharmaceutical composition that it is characterized in that containing the Chinese lantern plant steride chemical compound are made by 56~64% Chinese lantern plant steride chemical compound, 31~39% matrine and 2~9% Moschus by weight percentage.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200610010153 CN1864717A (en) | 2006-06-14 | 2006-06-14 | Method for extracting Chinese lantern plant steride and pharmaceutical composition thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200610010153 CN1864717A (en) | 2006-06-14 | 2006-06-14 | Method for extracting Chinese lantern plant steride and pharmaceutical composition thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1864717A true CN1864717A (en) | 2006-11-22 |
Family
ID=37423969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200610010153 Pending CN1864717A (en) | 2006-06-14 | 2006-06-14 | Method for extracting Chinese lantern plant steride and pharmaceutical composition thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1864717A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103445181A (en) * | 2013-09-17 | 2013-12-18 | 王喜军 | Application of physalis pubescens in preparing anti-fatigue and anti-hypoxia health-care food |
CN103933209A (en) * | 2014-04-03 | 2014-07-23 | 沈阳化工大学 | Method for extracting steroid saponin from Chinese lantern-plant stems and persistent calyx |
-
2006
- 2006-06-14 CN CN 200610010153 patent/CN1864717A/en active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103445181A (en) * | 2013-09-17 | 2013-12-18 | 王喜军 | Application of physalis pubescens in preparing anti-fatigue and anti-hypoxia health-care food |
CN103933209A (en) * | 2014-04-03 | 2014-07-23 | 沈阳化工大学 | Method for extracting steroid saponin from Chinese lantern-plant stems and persistent calyx |
CN103933209B (en) * | 2014-04-03 | 2018-03-13 | 沈阳化工大学 | A kind of method extracted in the stem from wintercherry fruit or calyx and detect steroid saponin |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102552396B (en) | Salvia miltiorrhiza Bunge var alba total phenolic acid extract, preparation method and application | |
CN1785384A (en) | Chinese medicinal composition for treating tuberculosis and its preparation method | |
CN1927293A (en) | Chinese medicine composition for treating skin burn and scald | |
CN1683358A (en) | Process for extracting total flavone from stem and leaf of scutellaria | |
CN1864717A (en) | Method for extracting Chinese lantern plant steride and pharmaceutical composition thereof | |
CN1931190A (en) | Toad skin extract and its medicine prepn and their prepn | |
CN100377731C (en) | Chinese traditional medicine and its preparation method and use | |
CN1251736C (en) | Chinese medicinal infusion for treating shingles, parotitis acute mamitis and its manufacturing method | |
CN106822338B (en) | Compound composition for reducing blood sugar and blood fat and preventing and/or treating diabetes and complications thereof and application thereof | |
CN114848750A (en) | Traditional Chinese medicine composition for improving immunity | |
CN101040997A (en) | Method for extracting leek seed total saponin and the application | |
CN104490965B (en) | The application of panax japonicus polysaccharides, panax japonicus total saponins and panax japonicus saponin V | |
CN101926842A (en) | Medicinal composition prepared from raw materials containing snow lotus and fermented cordyceps fungal powder | |
CN107693597B (en) | Traditional Chinese medicine composition for resisting myocardial ischemia and preparation method and application thereof | |
CN1927289A (en) | Pharmaceutical composition for treating diabetes and impaired glucose tolerance and its preparation | |
CN1274320C (en) | Notoginseng ginkgo health care food and its preparation method | |
CN1289104C (en) | Anticancer medicine and its preparation | |
CN1271994C (en) | Compound Chinese angelica root freeze-dried powder injectron and its preparing method | |
CN1973857A (en) | Chinese medicine red sage-astragalus root prepn for treating liver fibrosis and liver cirrhosis and its prepn process | |
CN1733107A (en) | Medicine for treating coronary disease and apoplexy sequelae and process for preparing the same | |
CN1254255C (en) | Oral liquor for curing cerebral hemorrhage and its preparation method by using leach | |
CN1634241A (en) | Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases and its preparing process | |
CN105311065A (en) | Application of aleuritopteris argentea extract in preparation of medicines for treating cardiovascular and cerebrovascular diseases | |
CN1273114C (en) | Sichuan aconite root freeze-dried powder injection and its preparing method | |
CN1883654A (en) | Pulse invigorating injection with astragalus root and preparation process thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |